• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Ipsen Reports Strong Q1 Sales, Affirms Full-Year Outlook

    GLOBENEWSWIRE

    Ipsen Highlights Early Immuno-Oncology Pipeline At AACR

    GLOBENEWSWIRE

    Ipsen Withdraws Tazverik In Lymphoma And Sarcoma

    GLOBENEWSWIRE

    HUTCHMED Updates On TAZVERIK Oncology Product In China

    GLOBENEWSWIRE

    Ipsen`s Iqirvo Sales Hit $200M; GENFIT Gets $20M Milestone

    GLOBENEWSWIRE

    Origami Pharma Teams Up With Ipsen For Protein Degrader Program

    BUSINESSWIRE

    Ipsen`s ADC push leads to $1B deal for preclinical Simcere drug

    GLOBENEWSWIRE

    Ipsen Puts up $1.6B to Absorb ImCheck for Leukemia Antibody

    BIOSPACE

    DETERA Therapeutics Wins The Ipsen Golden Ticket 2025

    GLOBENEWSWIRE

    Ipsen Gets EU OK for CABOMETYX in Neuroendocrine Tumors

    BUSINESSWIRE

    Ipsen Revises Executive Committee

    CONTRACTPHARMA

    IRIC and IRICoR Begin Phase 1 Trial for Solid Tumor Therapy

    PR NEWSWIRE

    Onivyde Regimen Linked to Long-Term Survival in Pancreatic Cancer

    GLOBENEWSWIRE

    Ipsen S.A. - Annual General Meeting held on 21 May 2025

    GLOBENEWSWIRE

    Ipsen taps Biomunex`s MAITs to treat solid tumors in $610M bet

    FIERCE BIOTECH

    Ipsen And Foreseen Biotech Sign Global License For Novel ADC

    GLOBENEWSWIRE

    Ipsen scores 2nd preclinical ADC via $1B biobucks pact with Foreseen

    FIERCE BIOTECH

    Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC

    PRESS RELEASE

    Latest PIII trial data investigating Cabometyx to be presented at ASCO GU 2024

    GLOBENEWSWIRE

    Ipsen updates on QM-1114 regulatory process

    GLOBENEWSWIRE

    Cabometyx with nivolumab shows durable survival benefits in renal cell carcinoma

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.